Addiction is yet another area where GLP-1s might be effective. Preliminary evidence looks promising, but questions remain.
Some of what RFK Jr. says about obesity prevention isn't new. But after having coined the catchy MAHA acronym, it’s likely ...
Glucagon-like peptide-1 (GLP-1) brands Wegovy and Zepbound, along with their counterparts approved for type 2 diabetes — Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro, respectively — have begun to ...
There’s no single GLP-1 diet plan you need to follow. If you’re taking — or thinking about taking — a GLP-1 medication like ...
Berberine, green tea extract and taurine are just some of the ingredients advertised as being able to ‘boost’ GLP-1 levels.
We recently compiled a list of the 10 High Growth Healthcare Stocks to Invest in Now. In this article, we are going to take a ...
A cross-sectional study of privately insured patients with obesity showed that the use of GLP-1 RAs soared from 2022 to 2023, ...
Viking Therapeutics shows strong data with VK2735, a potential competitor to major drugs. Discover why VKTX stock is a ...
Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data.
The table below is a review of notable updates that occurred in November 2024 for investigational products in development (not an inclusive list). Click on the status to view our full coverage. The ...
A study finds that anti-obesity medications may help reduce alcohol consumption, with nearly half of participants in weight ...
Anti-obesity medications may help reduce alcohol consumption, particularly in moderate and heavy drinkers, offering potential dual health benefits.